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Alzheimer’s disease (AD) and familial Danish dementia (FDD) are degenerative neurological diseases characterized by amyloid pathol-
ogy. Normal human sera contain IgG antibodies that specifically bind diverse preamyloid and amyloid proteins and have shown thera-
peutic potential in vitro and in vivo. We cloned one of these antibodies, 3H3, from memory B cells of a healthy individual using a
hybridoma method. 3H3 is an affinity-matured IgG that binds a pan-amyloid epitope, recognizing both A and  Ig light chain (LC)
amyloids, which are associated with AD and primary amyloidosis, respectively. The pan-amyloid-binding properties of 3H3 were dem-
onstrated using ELISA, immunohistochemical studies, and competition binding assays. Functional studies showed that 3H3 inhibits
both A and LC amyloid formation in vitro and abrogates disruption of hippocampal synaptic plasticity by AD-patient-derived soluble
A in vivo. A 3H3 single-chain variable fragment (scFv) retained the binding specificity of the 3H3 IgG and, when expressed in the brains
of transgenicmice using an adeno-associated virus (AAV) vector, decreased parenchymal A amyloid deposition in TgCRND8mice and
ADan (Danish Amyloid) cerebral amyloid angiopathy in the mouse model of FDD. These data indicate that naturally occurring human
IgGs can recognize a conformational, amyloid-specific epitope and have potent anti-amyloid activities, providing a rationale to test their
potential as antibody therapeutics for diverse neurological and other amyloid diseases.
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Introduction
Alzheimer’s disease (AD) and Familial Danish dementia (FDD)
are degenerative neurological diseases characterized by the depo-
sition of pathological amyloids. Amyloid deposits and inclusions
are characterized by the accumulation of normally soluble pro-
teins in insoluble fibrillar forms. They adopt a characteristic am-
yloid conformation, which is highly enriched for-pleated sheets
and exhibits green birefringence under polarized light when
stained with Congo red. Soluble preamyloid structures have also
been identified, which include both oligomers with relatively lit-
tle -pleated sheet structure and protofibrils (PFs) that have a
high degree of -pleated sheet structure. In AD, A oligomers
may be more toxic than amyloid fibrils (Lambert et al., 1998;
Walsh et al., 2002).
AD and FDD are examples of 30 human amyloid diseases
that range from common disorders such as AD to rare autosomal
disorders such as FDD (Chiti and Dobson, 2006). These diseases
produce amyloid proteins with entirely different sequences that
Received Dec. 16, 2014; revised Feb. 10, 2015; accepted Feb. 12, 2015.
Author contributions: Y.L., B.O.’N, R.D.P., T.O., S.P.A., C.C., S.M., D.M.W., R.V., A.S., D.B., M.J.R., T.E.G., and S.K.D.
designed research; Y.L., B.O.’N, R.D.P., T.O., S.P.A., C.C., P.E.C., A.M.R., S.M., and A.J.M. performed research; R.V. and
D.B. contributedunpublished reagents/analytic tools; Y.L., B.O.’N, R.D.P., T.O., and S.K.D. analyzeddata; Y.L., B.O.’N,
R.D.P., D.M.W., M.J.R., T.E.G., and S.K.D. wrote the paper.
This work was supported by Sharpe-Strumia Research Foundation (S.K.D.), the Edward N. and Della Thome
Memorial Foundation (T.G. and S.K.D.), NIH Grant AG18454 (T.G.), and Science Foundation Ireland (M.J.R.).
The content is solely the responsibility of the authors and does not necessarily represent the official views of
the National Institutes of Health. We thank Gordon Freeman (Dana Farber/Partners Cancer Care) for the
tCD40L cell line, Brenda D. Moore for preparing and characterizing various generic amyloids and fibrillar A,
Chandana Devi Kattala for laboratory assistance, and Gwen Gilliard with help with the brain IHC. Human
tissues used in Figure 2, m–t, were obtained from the University of Florida Neuromedicine Human Brain
Tissue Bank.
S.K.D. has stock ownership in a company (Immunome, Inc.) that has licensed the human monoclonal antibody
cloning method and the 3H3 antibody described here. He and S.P.A. are also inventors on patents related to the
hybridomamethod. The remaining authors declare no competing financial interests.
This article is freely available online through the J Neurosci Author Open Choice option.
Correspondence should be addressed to either of the following: Scott K. Dessain, Lankenau Institute for Medical
Research, 100 Lancaster Ave., Wynnewood, PA 19096, E-mail dessains@mlhs.org; or Yona Levites, Department of
Neuroscience, CTRND, College of Medicine, University of Florida, 1275 Center Drive, P.O. Box 100159, Gainesville, FL
32610, E-mail: levites.yona@ufl.edu.
DOI:10.1523/JNEUROSCI.5109-14.2015
Copyright © 2015 the authors 0270-6474/15/356265-12$15.00/0
The Journal of Neuroscience, April 22, 2015 • 35(16):6265–6276 • 6265
share conformational epitopes resulting from their -pleated
sheet structure (Kayed et al., 2003). Monoclonal antibodies
(mAbs) have been isolated that recognize these pan-amyloid con-
formers and have anti-amyloid activities (Hrncic et al., 2000;
O’Nuallain and Wetzel, 2002; O’Nuallain et al., 2011; Zhang et
al., 2011; Zhao et al., 2014). Human intravenous Ig’s (IVIGs)
derived from pools of plasma from healthy donors contain IgGs
that bind these epitopes (Du et al., 2001; Du et al., 2003;
O’Nuallain et al., 2006).We reported that A-reactive polyclonal
IgGs in IVIGs cross-reacted with different types of amyloid fibrils
and oligomers, including Ig light chain amyloid (AL) (O’Nuallain
et al., 2006; O’Nuallain et al., 2008). These antibodies impaired
A and AL fibrillogenesis in vitro and dissociated AL amyloid in
vivo. Experiments testing IVIG in transgenic AD mouse models
suggested that short-term or long-term treatments can benefit
cognitive function (Mengel et al., 2013; St-Amour et al., 2014).
Results of clinical testing of IVIG inmild tomoderateADpatients
have beenmixed, but a randomized trial suggested cognitive ben-
efits for moderate AD patients and APOE-4 carriers (Relkin,
2014).
These data support the hypothesis that conformation-specific
human IgGs exist and may have useful anti-amyloid properties.
However, it is not clear whether the conformational amyloid
binding and anti-amyloid capabilities observed with polyclonal
IVIGs can be replicated by individual mAbs or if these may con-
tribute to the potential utility of IVIG in AD (Relkin et al., 2009;
Magga et al., 2010; Sudduth et al., 2013; Gu et al., 2014).
Here, we report on the cloning, characterization, and func-
tional properties of an anti-amyloid IgG isolated frommemory B
cells of a healthy subject using a hybridoma method. This IgG
mAb, 3H3, recognized diverse amyloids, inhibited elongation of
A and LC amyloids, and reduced the disruption of synaptic
plasticity in the rat hippocampus by ADbrain extract. Expression
of a single-chain variable fragment (scFv) derived from 3H3, at-
tenuated A amyloid deposition in the brains of TgCRND8-
transgenic mice and cerebral amyloid angiopathy (CAA) from
ADan deposition in a mouse model of FDD. This study supports
further investigation of the clinical utility of naturally occurring
human mAbs that recognize conformational amyloid epitopes.
Materials andMethods
Proteins and polypeptides. Human A40 and S26C A40, a mutant A40
containing a cysteine in place of serine 26, which enables the formation of
a disulfide cross-linked dimer, [S26C A40]2 (O’Nuallain et al., 2010),
were purchased fromQuality Controlled Biochemicals. Wild-type (WT)
A40monomers,monomeric S26CA40, [S26CA40]2, [S26CA]2 PFs,
and A40 fibrils were generated as below and were used immediately or
frozen at80°C.WT and S26C peptide concentrations were determined
by absorbance at 275 nm using the molar extinction coefficient for ty-
rosine at 275 nm (e275 1400 M
1 cm1).
Before use, the lyophilized A40 was disaggregated by sequential ex-
posure to trifluoroacetic acid and hexafluoroisopropanol (Thermo
Fisher) followed by the addition of 2 mM NaOH and 2 PBS (1 final)
and ultracentrifuged to give a final peptide concentration of0.2mg/ml
(O’Nuallain et al., 2006). [S26C A40]2 was prepared by solubilizing the
S26C A40 peptide to0.2 mg/ml in MilliQ water (Millipore), diluted
1:1 with 20 mM ammonium bicarbonate, pH 8.2, to generate an20 M
(with respect to monomer) peptide solution, and bubbled with oxygen
for5–10 min. The peptide was incubated at room temperature for3
d and each day bubbled with oxygen.
WT and S26C A40monomers and [S26C A40]2 were isolated from
different sized A40 assemblies using size exclusion chromatography.
Peptides were incubated in 50 mM Tris-HCl containing 6 M guanidine
HCl, pH 8.0, to dissociate preexisting aggregates and then characterized
on a HiLoad 16/60 Superdex 75 column (GE Healthcare Bio-Sciences)
eluted at 0.8ml/min in 25mM ammonium acetate, pH 8.5 (O’Nuallain et
al., 2010). Fractions that contained A40 monomers or [S26C A40]2
were analyzed by SDS-PAGE using 16% polyacrylamide Tris-tricine gels
and silver staining (Shevchenko et al., 1996).
Meta-stable thioflavin T (ThT)-positive PFs were generated by dilut-
ing freshly isolated [S26C A40]2 to 0.1 mg/ml in 20 mM sodium
phosphate, pH 7.4, and incubating the reactionmixture for3 d at 37°C
(O’Nuallain et al., 2010). The reaction was monitored by ThT fluores-
cence and was judged complete when the fluorescent signal reached a
maximumplateauvalue (LeVine,1999).FormationofPFswasconfirmedby
electronmicroscopy and by the presence of ThT-positive aggregates in reac-
tion supernatants after centrifugation at 16,000 g for 20min.
JTO is a recombinant amyloidogenic 6 LC variable region cloned
from a multiple myeloma patient (Wall et al., 1999). JTO was produced
in an E. coli expression system and purified as described previously (Wall
et al., 1999). The soluble LC was sterile-filtered using a 0.22 m polyvi-
nylidene fluoride 25mmMillex-GV syringe-driven filter unit (Millipore)
and shown to be90% pure, consisting of monomers and dimers using
Sephadex G25 (GE Healthcare) gel filtration and SDS-PAGE. The pro-
tein concentration was determined by the MicroBCA assay (Thermo
Fisher).
WT A40 and JTO fibrils were generated by incubating 0.2 mg/ml
concentrations of the amyloidogenic proteins in PBS containing 0.02%
sodium azide, pH 7.4, at 37°C for 14 d [23]. Fibrillogenesis was judged
complete when ThT fluorescence reachedmaximum plateau values. The
reaction products were harvested by centrifugation at 20,200 g for 30
min at room temperature and fibril morphology confirmed by negative
contrast electron microscopy.
Amyloid fibrils derived from AL patient tissues and AD patient brain
plaque cores have been described previously (O’Nuallain et al., 2007;
O’Nuallain et al., 2008).
Cloning and initial characterization of 3H3 mAb. The 3H3 mAb was
cloned following previously described methods (Adekar et al., 2008b).
Work with human peripheral blood cells was performed under a proto-
col approved by theMain Line Hospitals Institutional Review Board and
consistentwith the principles set out in theWMADeclaration ofHelsinki
and the National Institutes of Health Belmont Report. After receipt of
informed consent, a blood sample fromahealthy adultmalewas collected in
heparin containing tubes. Peripheral blood mononuclear cells (PBMCs)
were isolated by gradient density centrifugation with FicollPaque Plus (GE
Healthcare). PBMCswere stored frozen in 90%heat-inactivated fetal calf
serum (Life Technologies) and 10% DMSO (Sigma-Aldrich) under liq-
uid nitrogen. Before cell fusion, CD27 cells were isolated with anti-
CD27magnetic beads (Miltenyi Biotec) according to the manufacturer’s
instructions and cultured for 8 d on a monolayer of tCD40L cells
(Urashima et al., 1995) (courtesy of Gordon Freeman, Dana Farber/
Partners Cancer Care) in IMDM supplemented with 10% human AB
serum, IL-4, IL-10, transferrin, gentamycin, insulin, and cyclosporine.
On day 8, cultured CD27 cells were electrofused to the B5-6T hetero-
myeloma cell line (Adekar et al., 2008a), plated in 96-well plates, and
selected in HAT medium (Sigma-Aldrich).
Hybridoma supernatants were screened by ELISAs with A40 or JTO
fibrils bound to 96-well high binding (Corning) plates at 4°C overnight
with 100 l/well at 5 g/ml in PBS. Specific IgG was detected with the
HRP-conjugated anti-human IgG monoclonal antibody (9040-05)
(Southern Biotechnology). Hybridoma supernatants that were positive
in ELISA were selected for subcloning by limiting dilution. After 3
rounds of subcloning, stable hybridomas were adapted to serum-free
medium (IS MAB-CD; Irvine Scientific), incubated for 5 d in a 500 ml
roller bottle. Filtered supernatants were purified over protein
G-Sepharose (GE Healthcare). Purity was assessed by SDS-PAGE
(Life Technologies) and shown to be90% pure. Protein concentra-
tions were determined using the NanoDrop spectrophotometer
(NanoDrop Technologies).
IgGheavy-chain (HC) and LC subtypeswere assessed by capture of the
antibodies with a polyclonal rabbit anti-human whole IgG (6145-01;
Southern Biotech) and identification of reactivity with the HRP-
conjugatedmouse anti-human IgG3monoclonal antibody (053620; Life
Technologies) and the  LC-specific HRP-conjugated goat anti-human
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polyclonal antibody (2070-05; Southern Biotech), respectively. For all
ELISAs, o-phenylenediamine was used as the colorimetric substrate; op-
tical density at 490 nm was measured using a BioTek ELISA reader.
Variable domain cDNA sequences of the 3H3 mAb were amplified
with consensus primer sets specific for human Ig heavy chains (Campbell
et al., 1992) and for  light chains (Coronella et al., 2000), as previously
described (Adekar et al., 2008b). DNA fragments were sequenced by the
Kimmel Cancer Center Nucleic Acid Facility, Thomas Jefferson Univer-
sity (Philadelphia, Pennsylvania) and analyzed using the V-Quest pro-
gram (Lefranc et al., 2005).
Direct and competitive assays of antibody binding to amyloids. Antibody
reactivity with wild-type A40 fibrils, S26C A40 monomers, [S26C
A40]2, monomeric A40, bovine elastin fibrils (Sigma-Aldrich), JTO,
and patient-derived A fibrils and LC amyloids was determined using a
europium (Eu3)-based fluoroimmunoassay (EuLISA) (Adekar et al.,
2010). The EuLISAwas performed with purified 3H3 in assay buffer (1%
BSA in PBSA containing 0.05% Tween 20) in activated high-binding
Costar microtiter plate wells coated with 400 ng of target protein and
blocked with 1% BSA (Sigma-Aldrich) in PBS. A biotinylated goat anti-
human IgG (-chain specific; Sigma-Aldrich) served as the secondary
antibody. After the addition of a Eu3 streptavidin conjugate, followed
by the releasing enhancement solution, Eu3 time-resolved fluorescence
was measured using a Victor2 1420 Multilabel Counter (PerkinElmer).
The amount (fM) of lanthanide released was calculated from a standard
curve using known concentrations of Eu3. All measurements were
done in triplicate (error bars in the figures represent SD) and antibody
half-maximal effective concentration (EC50) values were determined
from the sigmoidally fit binding curves (SigmaPlot 2000 ver. 8; Systat
Software).
For the competition binding studies, we used the Eu3 time-resolved
fluoroimmunoassay (Diamandis, 1988) incorporating Eu3-streptavidin
and time-resolved fluorometry (DELFIA system; PerkinElmer) as de-
scribed previously (O’Nuallain et al., 2006). Ninety-six-well plates were
coated with 400 ng of soluble or fibrillar protein or peptide and blocked
with 1% BSA in PBSA. The concentration of the antibody remained
constant in the presence up to a 100- to 50-fold molar excess of soluble
protein or peptide or 0.5–0.1 mg/ml fibrillar competitors. Biotinylated
goat anti-human IgG (Sigma-Aldrich) served as the secondary antibody.
Time-resolved fluorescence was measured as described above. Half-
maximal inhibitory concentration (IC50) values were determined by fit-
ting each titration dataset to a sigmoid equation using the SigmaPlot
2000 version 8 software package (Systat Software).
Human tissue samples and immunohistochemistry. Human brain sam-
ples, including pathologically confirmed AD cases, were obtained at au-
topsy, fixed in formalin, embedded in paraffin blocks, and sliced into
4- to 6-m-thick slices and placed on poly-L-lysine coated microscope
slides. Antigen retrieval was with Vecta stain antigen retrieval solution
(Vector Labs), boiled in a pressure cooker for 30min, blocked for 30min
at 37°C, developed with the Vector ABC kit (Vector Labs) and 3,3-
diaminobenzidene, followed by counterstaining with hematoxylin.
Staining of human kidney, heart, and spleen samples from patients with
amyloid deposition was performed on 4- to 6-m-thick sections cut
from formalin-fixed, paraffin-embedded blocks of amyloid-laden tissue
and placed on poly-L-lysine coated microscope slides for Congo red and
antibody staining. Antigen retrieval was performed by 30 min boiling in
Glyca solution (BioGenex). Tissues were exposed overnight at 4°C to 0.1
g/ml biotinylated 3H3 mAb in HEPES-buffered saline. Slides were de-
veloped using a Vectastain ABC kit (Vector Labs) and 3,3-diamino-
benzidene and examined with a Leica DM500 microscope.
Inhibition of fibril formation. To assay the formation of amyloid fibrils
in real time, we used ThT fluorescence to measure amyloid fibril forma-
tion in solution (Ban et al., 2003). Wells of an ultra-low-binding 96-well
plate (Corning) were filled with 15 M soluble A40 or 50 M JTO
monomer, 30 M ThT, and serial dilutions of the test antibodies (1.0
M-10 nM) in PBS containing 10 M ThT, pH 7.4 (Adekar et al., 2008b).
The plates were incubated at 37°C and fluorescence intensity was mea-
sured hourly for 5 h with the FL600 microplate reader.
Measurement of 3H3 binding kinetics. Off-rate screening and affinity
determination were performed on an Octet RED384 instrument (Pall
ForteBio). All measurements were performed at 30°C; 96-well micro-
plates were agitated at 1000 rpm. Various 3H3 or pan-A antibody dilu-
tions in a range of 10 nM to 1 mM were prepared in a new 384-well
microtiter plate for secondary screening.MonomericA40 orA42were
biotinylated using EZ-Link sulfo-NHS-LC-biotin (Thermo Fisher) ac-
cording to the manufacturer’s protocol and immobilized at a concentra-
tion of 50 g/ml on streptavidin sensors for 10 minutes. For off-rate
screening, sensors were blocked with 1% bovine serum albumin (Sigma-
Aldrich) for 5 min, transferred to the wells containing the antibody dilu-
tion for the association step (5min), and transferred back to the blocking
well for the measurement of the dissociation step (5 min). Dissociation
rate constants (koff) for each antibody concentration were calculated
applying a 1:1 interaction model (fitting local, full) using the ForteBio
data analysis software 7.0.1.5. Curves that could not be reliably fittedwith
the software (mostly full R 2 	 0.96), presumably due to heterogeneous
binding, were excluded from the analysis.
In vivo electrophysiology measurements of long-term potentiation. Ex-
periments were performed on groups of five to seven urethane-
anesthetized adult male Lister hooded rats, and were licensed by the
Department of Health and Children, Ireland. Single pathway recordings
of field EPSPs from the stratum radiatum in the CA1 area of the hip-
pocampus were evoked by stimulation of the ipsilateral Schaffer
collateral-commissural pathway (Klyubin et al., 2004). Test EPSPs were
evoked at a frequency of 0.033 Hz and at a stimulation intensity adjusted
to trigger an EPSP amplitude of 50% of maximum. The high-frequency
stimulation (HFS) protocol for inducing long-term potentiation (LTP)
consisted of 10 trains of 20 stimuli, interstimulus interval of 5 ms (200
Hz), intertrain interval of 2 s. The stimulation intensity during the HFS
remained unchanged. To inject samples, a cannula was implanted in the
lateral cerebral ventricle (coordinates 1 mm lateral to the midline and 4
mm below the surface of the dura) just before electrode implantation.
The preparation of the soluble AD brain extract and AD brain extract
immunodepleted of A used in the present experiments has been de-
scribed previously (Hu et al., 2014) and was obtained and used in accor-
dance with local institutional review board guidelines. For the
intracerebral coinjection paradigm, either 3H3 or the control antibody
was coincubated with the human AD brain extract for 10 min at room
temperature before the mixture was injected.
LTP is expressed as the mean 
 SEM percent baseline field EPSP
amplitude recorded over a 45 min baseline period. Statistical analysis
(GraphPad Prism version 6 for PC) comparing LTP values at 3 h post-
HFS was performed using one-way ANOVA followed by Holm–Sidak’s
multiple-comparisons post hoc tests.
Construction of a 3H3 scFv and expression in adeno-associated virus
(AAV). 3H3 scFv cDNA was synthesized at Blue Heron Biotechnology
based on mAb HC and LC variable domain sequences in VH-linker-VL
orientation and separated by a Gly4Ser3 linker. The scFv was cloned into
the pSecTag plasmid under control of the cytomegalovirus enhancer and
chicken -actin (CBA) promoter with an Ig  secretion leader at the N
terminus and c-Myc and 6xHIS tags at the C terminus, a Woodchuck
hepatitis virus posttranscriptional regulatory element, and the bovine
growth hormone polyA sequence (Levites et al., 2006a). Nonspecific scFv
(scFv ns) was obtained from a phage library (Medical Research Council)
and showed no affinity to A.
rAAV2/1 was prepared by standard methods. Briefly, pAAVs express-
ing the scFv were generated by transfection of the vector plasmid with
helper plasmids for serotype 1 in HEK293T cells (Levites et al., 2006a).
Forty-eight hours after transfection, cells were harvested and lysed in the
presence of 0.5% sodium deoxycholate and 50 U/ml benzonase (Sigma-
Aldrich) by freeze thawing; the virus was isolated using a discontinuous
iodixanol gradient and affinity purified on a HiTrap HQ column (GE
Healthcare). The genomic titer of each virus was determined by quanti-
tative PCR.
HEK cells were transfected with pSecTag scFv or pAAV scFv. Condi-
tioned media were collected 48 h later and cells were lysed in 1% Triton
X-100 with protease inhibitors. Media and cells were then subjected to
SDS-PAGE Western blotting analysis with chicken anti-c-myc (1:1000;
Invitrogen) as primary antibody. When expression was confirmed,
media from transfected cells was analyzed by direct ELISA method
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with A fibrils (100 ng/well) as capture and anti-c-myc-HRP (1:2000)
as detection.
Animal studies of rAAV2/1 expression. Animal husbandry procedures
were performed as approved by University of Florida Institutional Ani-
mal Care and Use Committee in an AAALAC-approved facility in accor-
dance with National Institutes of Health guidelines. To generate
TgCRND8 mice, male TgCRND8 mice containing double mutation in
human APP gene (KM670/671NL and V717F; Chishti et al., 2001) were
mated with female B6C3F1/Tac that were obtained fromTaconic. Geno-
typing was performed by PCR as described previously (Levites et al.,
2006b). Tg-ADan mice (TgFDD) and genotyping have been described
previously (Vidal et al., 2009). All animals were housed three to five to a
cage and maintained on ad libitum food and water with a 12 h light/dark
cycle.
Injection of neonatal mice was performed based on Chakrabarty et al.
(2013). Briefly, P0 pups were cryoanesthetized on ice for 5 min. 2 l of
rAAV2/1-scFv were injected intracerebroventricularly (ICV) into the
both hemispheres using a 10l Hamilton syringe with a 30 g needle. The
pups were then placed on a heating pad with their original nesting ma-
terial for 3–5 min and returned to their mother for further recovery. For
adult injections, mAb 3H3 (500 g, 1 mg/ml) was administered though
intraperitoneal injection to TgCRND8 mice.
Analysis of A or ADan in the brain. Biochemical and immunohisto-
chemical analyses of A in the brains of transgenic TgCRND8 and ADan
mice were performed as described previously (Levites et al., 2006a; Lev-
ites et al., 2006c). The following mAbs against Awere used in the sand-
wich capture ELISA for brainA40:monoclonal pan-A antibodymAb5
for capture and A40-specific mAb 40.1-HRP for detection (Levites et
al., 2006b). For brain A42, we used A42-specific mAb42.2 for capture
and mAb5-HRP for detection (Levites et al., 2006b). At the time of kill-
ing, the brains ofmice were divided bymidsagittal dissection and the first
hemibrain was used for biochemical analysis. Each hemibrain was se-
quentially extracted in a 3-step procedure with RIPA followed by SDS
followed by formic acid (FA) (Levites et al., 2006b).
Immunohistochemical staining was done using pan-A antibody
33.1.1 (1:1500) (Kim et al., 2007), glial fibrillary acidic protein (GFAP;
1:500; Millipore), anti-c-Myc (1;500; Life Technologies). The second
hemibrains were fixed in 4%paraformaldehyde in 0.1 M PBS, pH 7.6, and
then dissected and stained for visualization of A plaques (pan-AmAb
33.1.1, 1:500; Todd Golde), ADan deposits (rabbit polyclonal antibody
1700, 1:500; Ruben Vidal), GFAP (1:500; Millipore), Iba-1 (1:1000;
Wako Chemicals). For cerebrovascular amyloid detection, paraffin sec-
tions were stained with 1% Thio-S (Sigma-Aldrich).
Quantitation of A plaque burden and intensity of astrogliosis-
associated staining were calculated using the Positive Pixel Count pro-
gram (Aperio Technologies). At least three sections per sample, 30 m
apart, were averaged by a blinded observer to calculate plaque burden.
ForThio-S quantitation, three sections per samplewere used to count the
plaques or to calculate total positive pixel count using respective algo-
rithms. All of the above analyses were performed in a blinded fashion.
One-way ANOVA, followed by Dunnett’s multiple-comparison test,
were performed using the scientific statistic software Prism (version 3;
GraphPad Software). p-values	0.05 were considered significant.
Results
Binding of 3H3 to oligomeric A and LC fibrils
We performed a cell fusion using peripheral blood B cells ob-
tained from a healthy male in his 30s. Hybridomas secreting hu-
man IgG were screened for binding to A42 amyloid and an
amyloid formed from a recombinant LC variable domain 6
(JTO) (Wall et al., 1999). The IgG3 mAb 3H3 was cloned and
boundboth antigens (data not shown).DNA sequence analysis of
the variable domains revealed a HC complementarity determin-
ing region 3 (CDR3) length of 22 aa with 3.9% aa changes from
germline and an LC CDR3 length of 10 aa with 4.0% aa changes.
These features are typical of the antibodies produced by CD27
memory B cells circulating in peripheral blood (Klein et al., 1998).
We tested the binding of the 3H3 to A40 conformers using
an europium ELISA with plate-immobilized wild-type A40 fi-
brils, A40 monomers, S26C A40 dimers ([S26C A40]2), and
S26C A40 monomers, generated by -mercaptoethanol reduc-
tion of the dimeric peptide (Fig. 1a). S26CA40 is a synthetic A
peptide (1–40) containing cysteine in place of serine 26, which
can form a disulfide cross-linked dimer (O’Nuallain et al., 2010).
The binding curves demonstrated that the 3H3 mAb has nano-
molar reactivity with plate-immobilized A conformers and2-
fold weaker binding to the monomeric peptide. Calculated
EC50 values were as follows: WT fibrils, 6.0 
 0.02 nM, WT
monomers, 17 
 0.05 nM, [S26C A40]2, 6.0 
 0.04 nM, and
S26C A40 monomers, 9.1
 0.06 nM. A control, nonbinding
mAb (30B), which binds serotype B botulinum neurotoxin
(Adekar et al., 2008b), showed essentially no reactivity with
[S26C A40]2 (EC50  300 nM).
Because A40 conformationsmay be altered by binding to the
ELISA plate (O’Nuallain et al., 2007), we compared 3H3 binding
to soluble A40 aggregates using a competition binding ELISA
(Fig. 1b). We bound [S26C A40]2 to the plate and added 3H3
mAb in the presence of each of the following competitors: A40
fibrils, A40monomers, [S26CA40]2, or S26CA40 PFs. Bind-
ing of the 3H3 to the plate-immobilized [S26CA40]2 was inhib-
ited only by aggregated A and not by A monomers, with the
strongest inhibition provided by A40 fibrils and PFs. The calcu-
lated IC50 values were A40 fibrils: 0.62 
 0.03 g/ml, [S26C
A40]2: 8.4
 3.6 g/ml, S26C A40 PFs: 3.9
 0.28 g/ml, and
A40 monomers:40 g/ml. We assessed whether 3H3 bound
to elastin fibrils, which do not adopt an amyloid configuration
(Fig. 1c), comparing their binding to plate-immobilized A40
and JTO fibrils. The calculated EC50 values were A40 fibrils:
15
 0.05 nM, LC fibrils: 47
 0.50 nM, and elastin fibrils:300
nM. These data indicate that 3H3 preferentially binds amyloid
fibrils and aggregated A forms.Wemeasured the avidity of 3H3
antibody to biotinylated fibrillar A40 and A42, loaded onto
streptavidin sensors using the ForteBio Octet system (Ylera et al.,
2013). TheKDs for 3H3 binding to A40 fibrils (2.00 10
10 m)
and A42 fibrils (1.78  1010 m) were calculated based on kon
and koff rates.
Immunohistochemical assessment of 3H3 binding to diverse
amyloids in diseased tissues
Weused ELISA to test whether 3H3 could bind A amyloid from
AD patient brains and LC amyloid from AL patients. 3H3 bound
to AD patient fibrils from congophilic neuritic plaque cores as
well as to different LC species isolated from two AL patients, one
a 1 LC and the other a 3 LC (Fig. 1d). Calculated EC50 values
were AD plaques: 14
 0.05 nM, 1 LC fibrils: 14
 0.15 nM, and
3 LC fibrils: 123 
 10 nM, which are comparable to those ob-
served with the synthetic amyloids.
We assessed binding of 3H3 to pathologic amyloids in brain
tissues from patients with neurologic amyloid diseases. 3H3
bound plaques and blood vessels in the AD brain (Fig. 2b,e), but
not in normal brain (Fig. 2a,d). The 30B control mAb did not
bind any structures in the AD brain (Fig. 2c,f). 3H3 also bound to
amyloid deposited in brain tissue of patients with multiple sys-
tems atrophy, which is characterized by -synuclein-positive
glial cytoplasmic inclusions, AD with CAA, and progressive su-
pranuclear palsy, with neurofibrillary tangles containing tau,
whereas the pooled human IgG control did not bind to these
tissues (Fig. 2m–o). Naturally occurring antibodies in serum that
react with -synuclein or A plaques have been described in
healthy subjects (Britschgi et al., 2009; Besong-Agbo et al., 2013).
3H3 also bound to A plaques deposited in the brains of
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TgCRND8 mice, which express a mutant (K670N/M671L and
V717F) human APP695 transgene (Janus et al., 2000; Fig. 2).
We tested binding of 3H3 to non-neurological amyloids. The
3H3 mAb bound to kidney samples from PSA patients, one with
a 1 LC (Fig. 2g) and the other a 8 LC (Fig. 2h), whereas it did
not bind to normal kidney (Fig. 2i) and pooled human IgG did
not bind to any of these tissues (Fig. 2j–l). 3H3 bound cardiac
tissue affected by transthyretin deposition, as well as pathological
1 amyloid in kidney and 3 amyloid in spleen (data not shown).
These data suggest that the 3H3 mAb recognizes an amyloid-
specific conformational epitope that is present in amyloids of
different primary sequences in diseased tissue.
Inhibition of fibril formation
Antibody binding to amyloid epitopes can correlate with the abil-
ity to interfere with de novo growth (O’Nuallain et al., 2006;
Adekar et al., 2010). Therefore, we tested the ability of the 3H3
mAb to inhibit elongation of fibrils formed from A40 or JTO.
We first mixed A40 monomers with ThT, a molecule that fluo-
resces quantitatively when bound to amyloid fibrils, in the pres-
ence of serially diluted 3H3 or the 30B controlmAb (Fig. 3a,b). At
the higher mAb concentrations tested, 0.25–1.0 M, the 3H3 in-
hibited A40 fibril elongation, whereas the 30B mAb did not. At
the lower concentrations, 0.06 and 0.13 M, the time course for
Figure 1. mAb 3H3 is pan-reactive against immobilized A conformers but in solution only recognizes aggregated peptide. A, Antibody binding curves for 3H3 demonstrate the antibody’s low
nM reactivity with plate-immobilized A conformers, albeit2-foldweaker binding to themonomeric peptide. A control mAb, 30B, had essentially no reactivity with plate-immobilized A. S26C
A40 monomers were generated by-mercaptoethanol reduction of the dimeric peptide. Filled triangles, WT A40 fibrils; open squares, WT A40 monomers; open circles, S26C A40 dimers
([S26C A40]2) filled circles, S26C A40 monomers; all were tested with the 3H3 mAb. Filled diamonds, [S26C A40]2, tested for binding of the 30B control mAb. B, Representative competition
ELISA curves are shown for solution-phase A conformer’s inhibition of mAb 3H3 binding to plate-immobilized recombinant [S26C A40]2. Filled triangles, WT A40 fibrils; open circles, [S26C
A40]2; filled diamonds, S26CA40PFs; open squares,WTA40monomers.C, Antibodybinding curves for 3H3demonstrate the antibody’s similar lownM reactivity against plate-immobilizedA
(filled circles) and recombinant JTO LC amyloid fibrils (open circles), and inability to recognize nonamyloid elastin fibrils (open triangles). The calculated EC50 valueswere A40 fibrils: 15
 0.05 nM,
LC fibrils: 47
 0.50 nM, and elastin fibrils:300 nM.D, 3H3 binding curves show the antibody’s nM reactivity with plate-immobilized patient-derived A (filled circles),1 LC (open triangles) and
3 LC fibrils (filled triangles), with EC50 values of 14
 0.05 nM, 14
 0.15 nM and 123
 10 nM, respectively.
Figure 2. 3H3 binding to AD brain and AL kidney tissues. Normal (a, d) and AD brains (b, c,
e, f ) were stained with 3H3 (a, b, d, e) or the human nonbinding control IgG mAb, 30B (c, f ).
Plaques (P) and blood vessels (V ) are shown with arrows. (400). 3H3 was also tested for
binding to kidney samples from a patient with1 LC deposition (g),8 LC deposition (h), and
a normal subject (i). Pooled human serum IgG did not bind these tissues (j–l ). (200). (m–t)
3H3 (bottom row) was compared with pooled human IgG (top row) by immunohistochemistry
for binding to cortical tissue from patients and-transgenic mice. MSA (m, q) Multiple Systems
Atrophy -synuclein positive glial cytoplasmic inclusions; CAA (n, r) AD with CAA; PSS (o, s)
Progressive Supranuclear Palsy, tau-containingneurofibrillary tangles, CRND8 (p, t)mouse, the
TgCNRD8-transgenic mouse model with A plaques. The brown color indicates binding. Scale
bar, 500m, insets 50m.
Figure 2. Continued.
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Figure 2. Continued.
Figure 3. Dose-dependent inhibition of de novo A and LC amyloid fibril formation by subequimolar 3H3. A and LC monomers were incubated in the presence of dilution series of
the 3H3 and 30B mAbs. The progress curves for A (A, B) and LC (C, D) amyloid fibril formation show that 3H3 dose-dependently inhibited the formation of ThT positive amyloidogenic
aggregates, whereas the control 30B did not. The aggregation reactions were performed using 15 and 5M Amonomers and JTO  LC, respectively, in PBS containing 10M ThT, pH
7.2.
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fibril formation was delayed, although there was an increase in
the total amount of ThT fluorescence relative to the control. Sim-
ilar results were seen with JTO fibrils (Fig. 3c,d), with inhibition
of fibril growth at 0.5 and 1.0Mand elongation delay at 0.25M,
which also gave a greater final level of ThT fluorescence than the
control. 3H3 concentrations of 0.06 and 0.13M did not alter the
rate of ThT uptake by JTO. These findings indicate that the 3H3
mAb can inhibit A40 and JTO fibril growth.
Abrogation of the disruption of hippocampal synaptic
plasticity by soluble A in AD brain extract in vivo
Intracerebral injection of water-soluble A oligomers potently
inhibits LTP of synaptic transmission in the hippocampus, a neu-
rophysiological correlate of hippocampus-dependent memory
(Walsh et al., 2002; Shankar et al., 2008). Here, we assessed the
ability of 3H3 to acutely abrogate the inhibition of LTP by AD-
patient-derived soluble A oligomers at CA3-to-CA1 synapses in
the hippocampus of urethane-anesthetized rats (Cullen et al.,
1997; Klyubin et al., 2005). Electrically evoked field EPSPs
(EPSPs) were recorded for 1 h before the application of condi-
tioning HFS. Whereas LTP decayed gradually in animals that
received an intracerebroventricular injection of soluble A-
containing AD brain extract 15min beforeHFS, an identical HFS
protocol induced a stable, persistent increase in magnitude of
CA1 EPSPs in animals that received an injection of the same AD
patient brain soluble extract that had been immunodepleted of
A (p 	 0.01%, 107 
 4.3%, and 127.6 
 4.5% of pre-HFS
baseline, respectively, at 3 h post-HFS, n 7 per group; Fig. 4a,c).
The A-containing AD brain extract no longer inhibited LTP
(119.3
 3.0%, n 7, p	 0.05 compared with AD group) when
coadministered with a dose of the 3H3 mAb that did not affect
control LTP (p  0.05 compared with the immunodepleted-
alone group, 123.2
 1.3%, n 6; Fig. 4b,c). Coadministration of
the same amount of the control 30BmAbdid not affect the ability
of the soluble A in AD brain extract to inhibit LTP (106.2 

4.4%, n  5, data not shown). These results suggest that 3H3
mitigates the disruptive effect of AD-patient-derived, soluble A
oligomers on hippocampal LTP.
Studies of in vivo expression of 3H3 scFv in the TgCRND8
and ADan mice
We converted the 3H3 into an scFv for in vivo expression using
the AAV system. Neonatal injection of AAVs into the brains of
mice evades the host immune response and enables persistent
transgene expression. We cloned the variable regions of the 3H3
scFv into the mammalian expression vector pSecTag and the
plasmid, which drives expression from the CBA promoter and
provides C-terminal c-Myc and 6xHis tags. After transfection of
HEK cells with pSecTag-3H3 and pAAV-3H3, analysis of scFv
secreted in cell culture media was performed by ELISA in tripli-
cate. Secreted scFv preferentially bound to A fibrils relative to
monomers in an ELISA: pSecTag-3H3 (OD450 fibrils: 0.354 

0.024, OD450 monomer: 0.056 
 0.012), pAAV-3H3 (OD450
fibrils: 1.089
 0.067, OD450monomer: 0.187
 0.037), pan-Ab
scFv9 (OD450 fibrils: 0.542
 0.034, OD450 monomer: 0.983

0.005; Levites et al., 2006a). This confirms that the scFv replicated
the binding specificity of the intact IgG and suggests that the
recognition of A aggregates by 3H3 results from canonical Ig
binding activity.
Four microliters of a pAAV-3H3 scFv solution (1013 ge-
nomes/ml) was delivered into the cerebral ventricles of newborn
TgCRND8 pups. At 5 months, an age by which substantial amy-
loid pathology typically develops in these mice, we extracted
brains and processed them for immunohistochemical and bio-
chemical analysis. We evaluated scFv expression in the brains of
the injection group using the anti-c-Myc antibody (Fig. 5a–c). All
mice in this group had widespread brain expression of the scFv,
particularly in the hippocampus and cortex. We assessed the ef-
fects of 3H3 scFv expression onAplaque deposition.We stained
Figure 4. 3H3 abrogates the disruption of hippocampal synaptic plasticity by soluble A in
AD brain extract. A, Synaptic field potentials (EPSPs) were recorded from the CA1 area of anes-
thetized rats. The acute intracerebroventricular injection (#) of AD brain TBS extract (AD, filled
circles, n 7) 15 min prior high-frequency stimulation (HFS) conditioning (arrow) strongly
inhibited LTP comparedwith brain extract that had been effectively immunodepleted (ID) of all
detectable A, see (Hu et al., 2014) (ID, open circles, n 7).B, Coinjection of 3H3 antibody (10
g) prevented the inhibition of LTP by soluble A-containing AD brain extract (AD3H3,
closed circles, n 7). When coinjected with ID extract, 3H3 did not affect LTP (ID3H3, open
circles,n6).C, Summary LTPdata at 3hpost-HFS for all experimental groups shown in (A,B).
*p	 0.05 and **p	 0.01. Values are mean
 SEM.
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Figure 5. 3H3 scFvs attenuates A deposition in 5month-old CRND8mice. Newborn CRND8mice were injected ICV with AAV 3H3 scFv (4 10 10 genomes/mouse). Control mice received PBS.
Fivemonths later, themicewere killed andanalyzed.Onehemibrainwasused for immunohistochemistry and theother for biochemical analysis. scFv expression in thebrainwasdetectedby staining
for the c-Myc tag. The photomicrographs are representative sections of groups of 7–10mice: (a) PBS (b, c) 3H3 scFv. Magnification 10. Representative brain sections from PBS (d, f ) or 3H3 scFv
(e, g) injectedmice were stainedwith pan-AmAb (33.1.1) (d, e) or the A40 specific mAb (13.1.1) (f, g). Magnification 2 and 5 (insets 5 and 20). (h) 3H3 scFv expression surrounding
amyloid plaqueswas visualized by staining for c-Myc tag.Magnification 20 (i) A40 and A42 levels in brain extracts solubilizedwith RIPA buffer, SDS, or formic acid (FA), analyzed by sandwich
ELISA n 5. *p	 0.05 vs control. (j) A plaque burden analysis was performed on three nonconsecutive sections from each mouse in the group. n 7–10.
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brain sections from PBS-injected (Fig. 5d,f) or pAAV-3H3 scFv-
injected mice (Fig. 5e,g) with either a pan-AmAb (Fig. 5d,e) or
an A40-specific mAb (Fig. 5f,g). We did not observe clear dif-
ferences in the number of plaques present. However, the plaque
morphology in the pAAV-3H3 scFv-injected mice was more dif-
fuse (Fig. 5f,g). In the injected mouse brains, the plaques were
decorated by the 3H3 scFv, as visualized by anti-c-Myc staining
around the plaques (Fig. 5h).
We assessed the total amyloid burden by measuring amyloid
A levels in RIPA-soluble, SDS-soluble, and FA-soluble brain
fractions by ELISA (Fig. 5i). A40 levels were significantly lower
in the SDS and FA extracts from the AAV-3H3 scFv-injected
mice, compared with the control mice, but a statistically signifi-
cant change was not observed in A42 levels in the SDS and FA
extracts or in the A40 or A42 levels in the RIPA-extracted
fractions. Quantification of the total A40 plaque burden on
brain sections of control and scFv-expressing mice also did not
show a significant difference (Fig. 5j).
We extended these results by delivering the pAAV-3H3 scFv
in ADan mice, in which the Danish amyloid subunit comprising
the last 34 aa of human BRI2 is expressed under the control of the
mouse prion protein promoter. ADan mice show significant in-
tracellular and extracellular deposition of oligomeric forms of
ADan, including vascular amyloid deposition, parenchymal
ADan deposition, and amyloid associated gliosis (Vidal et al.,
2009). We injected newborn ADan mice with 4 l of pAAV-3H3
scFv (1013 genomes/ml). Control mice were injected with PBS.
Expression of scFv was confirmed by anti-c-Myc brain staining 3
weeks after injection in 3 mice and remaining mice were aged to
12months. At that time, brains were harvested and effects of scFv
on development of pathology were evaluated. Control mice de-
veloped significant Thio-S-positive CAA in the meninges, thala-
mus, and cerebellum, whereas 3H3 scFv-expressingmice had less
CAA pathology in these tissues (Fig. 6a). Quantification of
reduction in Thio-S-positive total positive signal as well as the
number of Thio-S-labeled blood vessels revealed statistically
significant reductions in the 3H3 scFv-expressing mouse
brains (Fig. 6b).
Mutant ADan amyloid deposits in ADan mice can be visual-
ized by binding with antibody 1700 (rabbit polyclonal; Vidal et
al., 2009). In the controlmice, typical stainingwas observed in the
hippocampus as well as in the blood vessels in the cerebellum,
whereas mice expressing 3H3 scFv had virtually no amyloid-like
deposits in the hippocampus and less ADan-positive CAA in the
cerebellum (Fig. 6c). Importantly, 3H3 scFv expression corre-
lated with reduced astrocytosis in the brains of the mice, as dem-
onstrated by decreased GFAP staining in the hippocampus,
midbrain, and cerebellum (Fig. 6d).
Discussion
The 3H3 mAb is a human monoclonal antibody, cloned from a
healthy subject, that binds multiple amyloids, regardless of the
primary sequence of the protein subunits. The 3H3 demon-
strated anti-amyloid activity in vitro and in three in vivo model
systems. Therefore, the 3H3 recapitulates essential features of
amyloid-binding IgGs previously identified in polyclonal IVIG
(O’Nuallain et al., 2006; Britschgi et al., 2009; Dodel et al., 2011).
Because 3H3 was identified by its recognition of JTO Ig LC and
A42 amyloids, it represents just one of the many types of anti-
amyloid antibodies that may exist in IVIG. Nonetheless, the 3H3
demonstrates that potentially therapeutic features of IVIG can be
embodied in a humanmAb thatmay be adaptable for therapeutic
use.
The 3H3originated fromaCD27peripheral bloodB cell and
has somatically mutated variable domains, indicating that it had
undergone T-cell-dependent antibody affinity maturation and is
therefore the product of the adaptive immune response. The
amyloid-specific binding of the 3H3 scFv indicates that recogni-
tion of the conformational amyloid epitope occurs through the
canonical CDR-binding domains, not Fc-mediated interactions,
as has been reported for at least one amyloid protein (Huang et
al., 1993). The observation that IgGs with similar features can be
found in children, in addition to IVIG, suggests that IgG-binding
conformational amyloid epitopes are the products of the normal
immune response to amyloids (Baril et al., 2004).
In the live rat model of hippocampal LTP, 3H3 abrogated the
synaptotoxicity of soluble A oligomers contained in an AD-
brain extract. Soluble A species extracted from human brains
are pathophysiologically relevant material for modeling key fea-
tures of AD (Shankar et al., 2008). The ability of the 3H3mAb to
inhibit their toxicity on a living brain demonstrates one mecha-
nism whereby naturally occurring, conformation-specific anti-
bodies in IVIG may exert a protective function in AD. Murine
conformation-specific mAbs have also shown activity in the rat
model of A synaptotoxicity (Klyubin et al., 2008; O’Nuallain et
al., 2011).
In the TgCRND8-transgenic mouse model of CNS A depo-
sition, expression of the 3H3 scFv significantly reduced the levels
of SDS- and FA-extractable A40, but had no statistically signif-
icant change in A42 levels. This selective effect on A40 is con-
sistent with selective targeting of A amyloid because A40 is
more selectively deposited in cored amyloid plaques, whereas
A42 deposits in both cored amyloid plaques and more diffuse
immunoreactive deposits that are not congophilic. Indeed, a
change in plaque morphology was noted in the mice expressing
the 3H3 scFV because the plaques appeared less compact and
more diffuse. The 3H3 scFV was observed to surround A
plaques in the brain, suggesting that it may inhibit amyloid for-
mation by plaque binding. In brains of AD patients, colocaliza-
tion of IgGs with A neuritic plaques has been observed and
patients with high IgG plaque labeling had significantly reduced
A plaque burdens (Kellner et al., 2009).
In the FDDmodel of CAAdeposition in ADanmice, 3H3 scFv
expression reduced amyloid deposition and CAA while reducing
inflammation-associated expression of GFAP. Others have
shown that AAV delivery of an anti-amyloid scFv preferentially
targeting A42 oligomers can reduce A42 in the hippocampus
in the TgAPPswe/PS1dE9 mouse model of AD, although it ex-
acerbates CAA (Kou et al., 2011). These different results may be
attributable to particular binding properties of the scFvs and the
use of different models. It is unlikely that the 3H3 scFv could
induce glial clearance of A because it lacks effector functions.
Additional efforts to add effector functions, increase affinity, or
increase the concentrations of the scFv in vivo may enhance its
anti-amyloid activity. In any case, our data with the 3H3 scFv
indicates that pan-amyloid scFv antibodies can attenuate deposi-
tion of different amyloids in vivo.
The finding that 3H3 bound to plate-immobilized mono-
meric A in a direct ELISA may seem paradoxical given the
strong evidence for its binding to a pan-amyloid conformational
epitope; for example, binding to diverse amyloid oligomers and
preferential binding to oligomeric A in competition binding
studies. One explanation is that, when A binds the 3H3 anti-
body, the bound A has an amyloid-like conformation that was
induced by plate immobilization (O’Nuallain et al., 2007; Szabo
et al., 2010). The differential effects of 3H3 at different concen-
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Figure6. 3H3 scFv expressionprevents development of pathology inADan-transgenicmice. (a). NewbornADan-transgenicmicewere injected into cerebral ventricleswith pAAV - 3H3 scFv (4
10 10 genomes/mouse) and killed at 12 months of age. CAA pathology in blood vessels was visualized with Thio-S in the hippocampus (top panels), thalamus (middle panels), and cerebellum
(bottom) ofmice injectedwith PBS or pAAV-3H3 scFv. (b) Quantification of fluorescence positive signal (left) and number of Thio-S positive blood vessels (right), showing decreases in the 3H3-scFv
group compared with PBS-injected mice (n 5–7/group). (*p	 0.05, t test). Data are shown as the mean
 SEM (c) An anti-ADan polyclonal antibody 1700 was used to detect ADan peptide
accumulation in the hippocampus and cerebellar blood vessels of PBS treated and 3H3-scFv-expressing mice. (d). GFAP was analyzed by immunohistochemistry in brains of 3H3-scFv expressing
mice, compared with age-matched controls, in hippocampus (top), thalamus (middle) and cerebellum (bottom).
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trations on A and JTO amyloid formations provide indirect
support for this assertion. At low concentrations, 3H3 delayed
fibril formation but increased the total amount of amyloid
formed, whereas at higher concentrations, amyloid formation
was inhibited. It is possible that such effects could be explained by
3H3 convertingmonomeric A and JTO intomore uniform am-
yloid seeds, which could increase the lag time for aggregation but,
once seeded, enable more uniform and efficient assembly. These
3H3-induced seeds couldbe structurally different fromtheuninhib-
itedamyloid rections, resulting in slower reactionsanddifferentThT
reaction product yields. At higher 3H3 concentrations, sequestra-
tion of JTO and A would lower concentrations of free monomer
and inhibit overall amyloid formation.
The potent in vitro and in vivo anti-amyloid activities of 3H3
demonstrate that amyloids can be therapeutically targeted
through epitopes that are independent of the primary sequence of
the amyloid polypeptide. This offers the potential to treat amy-
loid diseases with mAbs that specifically bind toxic oligomeric
forms and not to nontoxic, nonaggregated forms. A mAb with
specificity for multimeric A, similar to the 3H3 in competition
assays, reduced amyloid deposition and A protofibril levels in a
transgenic mouse model expressing both the Arctic and Swedish
A mutations (tg-ArcSwe) (Englund et al., 2007; Lord et al.,
2009).
In this study, 3H3 demonstrated activity in animal models
intended to reproduce essential features of AD and FDD. Binding
to patient-derived Ig LC amyloids in vitro and in pathological
tissue sections further suggests that 3H3may be helpful for treat-
ment of other amyloid diseases such as primary amyloidosis, in
which the LC amyloids are deposited in extracellular tissues that
are accessible to the blood circulation. Proof-of-concept of the
ability of a mAb specific for an amyloid epitope to clear LC amy-
loids in vivo has been established using a mouse model in which
patient-derived amyloids were introduced by subcutaneous in-
jection (Hrncic et al., 2000).mAbopsonization andmacrophage-
dependent clearance of tissue-deposited amyloids has been
demonstrated in amousemodel of amyloidosis induced by over-
expression of serum amyloid P component (Bodin et al., 2010).
In conclusion, we have isolated an affinity matured human
mAb that binds a pan-amyloid epitope and has binding specific-
ity for aggregated amyloid forms. The mAb has anti-amyloid
activities in vitro and in vivo, suggesting that naturally occurring
anti-amyloid antibodies such as 3H3 may be protective and have
potential as anti-amyloid therapeutics.
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